HMGvsKisspeptin-54

Human Menopausal Gonadotropin is a purified urinary extract containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, sourced from the urine of postmenopausal women. After menopause, the loss of ovarian negative feedback (estradiol and inhibin) results in dramatically elevated pituitary gonadotropin secretion — FSH and LH levels rise 10-20 fold, providing a natural source of these hormones for pharmaceutical extraction.

The FSH component binds to FSH receptors (FSHR) on Sertoli cells in males and granulosa cells in females. FSHR is a Gs-coupled GPCR that activates cAMP/PKA signaling, driving the expression of genes essential for gametogenesis. In males, FSH-stimulated Sertoli cells produce androgen-binding protein (which concentrates testosterone locally), inhibin B (which provides negative feedback to the pituitary), and multiple growth factors that support spermatogonial proliferation and differentiation through the stages of spermatogenesis. In females, FSH drives follicular development — stimulating granulosa cell proliferation, estradiol synthesis via aromatase induction, and the growth of ovarian follicles from the pre-antral to the pre-ovulatory stage.

The LH component acts on Leydig cells in males (stimulating testosterone production via the LHCGR/cAMP/StAR steroidogenic pathway) and on theca cells in females (stimulating androgen precursor production that granulosa cells convert to estradiol). In females undergoing fertility treatment, the LH component is also critical for final oocyte maturation and ovulation triggering. The combination of both FSH and LH activity in HMG provides more complete gonadal stimulation than either gonadotropin alone — FSH drives the cellular proliferation and maturation processes while LH provides the steroidogenic and final maturation signals. This dual activity is why HMG is sometimes preferred over purified FSH preparations in certain fertility protocols, particularly in hypogonadotropic patients who lack endogenous LH.

Kisspeptin-54 is the full-length bioactive form of kisspeptin, cleaved from the 145-amino-acid precursor protein encoded by the KISS1 gene. It binds to KISS1R (GPR54) on GnRH neurons in the hypothalamic arcuate and anteroventral periventricular nuclei with the same binding site as KissPeptin-10 but with greater receptor affinity and a longer duration of action due to its extended peptide chain providing additional receptor contacts.

KISS1R is a Gq/11-coupled GPCR that activates phospholipase C upon kisspeptin binding, generating IP3 and DAG. IP3-mediated calcium release and DAG-activated PKC depolarize GnRH neurons, triggering robust GnRH pulse secretion into the hypophyseal portal blood supply. This GnRH pulse then stimulates anterior pituitary gonadotrophs to release both LH and FSH. The 54-amino-acid form produces a more sustained and robust GnRH/LH response compared to KissPeptin-10, attributed to its longer receptor occupancy time and potentially slower dissociation kinetics.

In clinical research, kisspeptin-54 has shown particular promise in reproductive medicine. A single bolus injection can trigger an LH surge sufficient for oocyte maturation in IVF protocols — potentially replacing the traditional HCG trigger with lower risk of ovarian hyperstimulation syndrome (OHSS), because kisspeptin's effect is physiological (triggering endogenous GnRH and LH) rather than pharmacological (directly mimicking LH like HCG). In functional hypothalamic amenorrhea (where stress or low body weight suppresses the reproductive axis), kisspeptin-54 infusion can restore LH pulsatility, confirming that the GnRH neurons remain responsive and the defect lies upstream at the kisspeptin level. The longer half-life of kisspeptin-54 compared to kisspeptin-10 (due to greater resistance to matrix metalloproteinases that degrade kisspeptins) makes it more practical for clinical applications where sustained receptor activation is desired.